Latest & greatest articles for esomeprazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on esomeprazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on esomeprazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for esomeprazole

21. Efficacy of esomeprazole for treatment of poorly controlled asthma.

Efficacy of esomeprazole for treatment of poorly controlled asthma. 19357404 2009 04 09 2009 04 15 2016 12 15 1533-4406 360 15 2009 Apr 09 The New England journal of medicine N. Engl. J. Med. Efficacy of esomeprazole for treatment of poorly controlled asthma. 1487-99 10.1056/NEJMoa0806290 Gastroesophageal reflux is common among patients with asthma but often causes mild or no symptoms. It is not known whether treatment of gastroesophageal reflux with proton-pump inhibitors in patients who have (...) poorly controlled asthma without symptoms of gastroesophageal reflux can substantially improve asthma control. In a parallel-group, double-blind trial, we randomly assigned 412 participants with inadequately controlled asthma, despite treatment with inhaled corticosteroids, and with minimal or no symptoms of gastroesophageal reflux to receive either 40 mg of esomeprazole twice a day or matching placebo. Participants were followed for 24 weeks with the use of daily asthma diaries, spirometry performed

NEJM2009 Full Text: Link to full Text with Trip Pro

22. Nexium (esomeprazole magnesium) For Delayed-Release Oral Suspension

Nexium (esomeprazole magnesium) For Delayed-Release Oral Suspension Drug Approval Package: Nexium (esomeprazole magnesium) NDA #022101 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Nexium (esomeprazole magnesium) For Delayed-Release Oral Suspension Company: AstraZeneca LP Application No.: 022101 Approval Date: 2/27/2008 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF

FDA - Drug Approval Package2008

24. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole

Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole BACKGROUND: The use of non-steroidal anti-inflammatory drugs (NSAID) is associated with an increased risk of gastric ulcer (GU) development. METHODS: This multicentre, randomized, double-blind, parallel-group trial compared endoscopic healing rates at 4 and 8 weeks after treatment with oral esomeprazole 40 or 20 mg once daily, or ranitidine (...) 150 mg twice daily, in patients with 1 baseline GU > or = 5 mm but no GUs or duodenal ulcers >25 mm in diameter who received continued cyclooxygenase-2-selective or non-selective NSAID therapies. The primary outcome was the percentage of patients in each treatment group who had no GUs at week 8. RESULTS: Four hundred and forty patients were randomized to treatment. At week 8, GU healing rates (95% CI) with esomeprazole 40 mg, esomeprazole 20 mg and ranitidine were 85.7 (79.8-91.7)%, 84.8

EvidenceUpdates2007

26. Aspirin plus esomeprazole reduced recurrent ulcer bleeding more than clopidogrel in high risk patients

Aspirin plus esomeprazole reduced recurrent ulcer bleeding more than clopidogrel in high risk patients Aspirin plus esomeprazole reduced recurrent ulcer bleeding more than clopidogrel in high risk patients | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aspirin plus esomeprazole reduced recurrent ulcer bleeding more than clopidogrel in high risk patients Article Text Therapeutics Aspirin plus esomeprazole reduced recurrent ulcer bleeding more than clopidogrel in high risk patients Free Walter L Peterson , MD Statistics from Altmetric.com

Evidence-Based Medicine (Requires free registration)2006

27. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials

Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials Gralnek I M, Dulai G S, Fennerty M B, Spiegel B M CRD summary This review concluded that while there was a statistically significant (...) improvement with esomeprazole compared with other proton-pump inhibitors in healing and symptoms, the clinical benefit was modest and may be more important in severe than mild erosive esophagitis. The overall conclusion appears reliable but the conclusion about the influence of disease severity should be viewed with caution. Authors' objectives To assess the effect of esomeprazole compared with other proton- pump inhibitors (PPIs) on healing rates, symptom relief and adverse events in the treatment

DARE.2006

28. A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori

A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori Wang X, Fang J Y, Lu R, Sun D F CRD summary The authors concluded that esomeprazole-based triple therapy may be as effective as omeprazole-based therapy (...) in eradicating Helicobacter pylori, and was well tolerated. There were limitations to this review that appear to undermine the reliability of these conclusions. Authors' objectives To compare the effects of esomeprazole-based therapy and alternative proton-pump inhibitor (PPI)-based therapy on Helicobacter pylori (H. pylori) eradication rates. Searching MEDLINE, EMBASE, the Cochrane Library and the Chinese Biomedical Database were searched from 2000 to 2005 using the reported search terms. In addition

DARE.2006

29. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis. A comparison of esomeprazole with other PPIs

Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis. A comparison of esomeprazole with other PPIs Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis. A comparison of esomeprazole with other PPIs Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis. A comparison of esomeprazole with other PPIs Edwards S J, Lind T, Lundell L CRD summary This review compared the effectiveness of esomeprazole (...) with other standard-dose proton-pump inhibitors for the treatment of reflux oesophagitis, and found that 40 mg esomeprazole is the most effective treatment currently available. Overall, the findings of the review appear to be supported by the data, but caution is advised given the levels of unexplained statistical variation detected between the studies. Authors' objectives To compare the effectiveness of esomeprazole with other proton- pump inhibitors (PPIs) for the treatment of reflux oesophagitis

DARE.2006

32. Esomeprazole did not universally improve asthma outcomes in moderate to severe stable asthma

Esomeprazole did not universally improve asthma outcomes in moderate to severe stable asthma Esomeprazole did not universally improve asthma outcomes in moderate to severe stable asthma | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Esomeprazole did not universally improve asthma outcomes in moderate to severe stable asthma Article Text Therapeutics Esomeprazole did not universally improve asthma outcomes in moderate to severe stable asthma Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish

Evidence-Based Medicine (Requires free registration)2006

33. Six-month management of patients following treatment for gastroesophageal reflux disease symptoms: a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical pra

Six-month management of patients following treatment for gastroesophageal reflux disease symptoms: a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical pra Six-month management of patients following treatment for gastroesophageal reflux disease symptoms: a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general (...) medical practitioners setting Six-month management of patients following treatment for gastroesophageal reflux disease symptoms: a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting Hansen A N, Wahlqvist P, Jorgensen E, Bergheim R, Fagertun H, Lund H, Moum B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each

NHS Economic Evaluation Database.2005

34. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.

Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. 15659723 2005 01 20 2005 01 27 2014 11 20 1533-4406 352 3 2005 Jan 20 The New England journal of medicine N. Engl. J. Med. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. 238-44 Concurrent therapy with a proton-pump inhibitor is a standard treatment for patients receiving aspirin who are at risk for ulcer. Current U.S. guidelines also recommend clopidrogel for patients who have (...) major gastrointestinal intolerance of aspirin. We compared clopidogrel with aspirin plus esomeprazole for the prevention of recurrent bleeding from ulcers in high-risk patients. We studied patients who took aspirin to prevent vascular diseases and who presented with ulcer bleeding. After the ulcers had healed, we randomly assigned patients who were negative for Helicobacter pylori to receive either 75 mg of clopidogrel daily plus esomeprazole placebo twice daily or 80 mg of aspirin daily plus 20 mg

NEJM2005

35. Nexium I.V. (Esomeprazole Sodium) Injection

Nexium I.V. (Esomeprazole Sodium) Injection Drug Approval Package: Nexium I.V. (Esomeprazole Sodium) NDA #021689 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Nexium I.V. (Esomeprazole Sodium) Injection Company: AstraZeneca LP Application No.: 021689 Approval Date: 03/31/2005 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: August 06, 2007 Note: Documents in PDF format require the . - - Links on this page: Note: If you

FDA - Drug Approval Package2005

36. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND study

Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND study Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND study Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg (...) technology The study compared the use of esomeprazole 20 mg "on-demand"(Nexium; AstraZeneca) versus continuous (over a 6-month period) treatment with lansoprazole 15 mg once daily (Zoton Capsules; Wyeth). Esomeprazole is the s-isomer of omeprazole, a proton-pump inhibitor (PPI) licensed for on-demand use in patients with endoscopy-negative gastro-oesophageal reflux disease (GERD). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients with heartburn as

NHS Economic Evaluation Database.2004

38. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies

Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand (...) esomeprazole with conventional omeprazole strategies Wahlqvist P, Junghard O, Higgins A, Green J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three strategies for the treatment of patients with gastro-oesophageal reflux disease (GORD

NHS Economic Evaluation Database.2002

39. Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK

Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK Wahlqvist P, Junghard O, Higgins A, Green J Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health interventions examined in the study were esomeprazole (40 mg once daily) and omeprazole (20 mg once daily) for the acute treatment of reflux oesophagitis. Type of intervention Treatment. Economic study type Cost-effectiveness analysis

NHS Economic Evaluation Database.2002

40. Nexium (Esomeprazole Magnesium) Delayed-Release Capsules

Nexium (Esomeprazole Magnesium) Delayed-Release Capsules Drug Approval Package: Nexium (Esomeprazole Magnesium) NDA #21-153 & 21-154 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Nexium (Esomeprazole Magnesium) Delayed-Release Capsules Company: AstraZeneca LP Application No.: 21-153 & 21-154 Approval Date: 2/20/2001 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Clinical Pharmacology

FDA - Drug Approval Package2001